Alumis Inc. (“Alumis” or the “Company”) (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced the pricing of its initial public offering of 13,125,000 shares of common stock at an initial public offering price of $16.00 per share. All shares of common stock are being offered by Alumis. In addition, Alumis has granted the underwriters a 30-day over-allotment option to purchase up to an additional 1,968,750 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
The shares are expected to begin trading on Nasdaq on June 28, 2024 under the symbol “ALMS.” The offering is expected to close on July 1, 2024, subject to the satisfaction or waiver of customary closing conditions.
Morgan Stanley, Leerink Partners, Cantor and Guggenheim Securities are acting as joint book-running managers for the offering.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.